Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function.

被引：0

作者：

Weber, Donna

Wang, Michael

Chen, Christine

Belch, Andrew

Stadtmauer, Edward A.

Niesvisky, Ruben

Yu, Zhinuan

Olesnyckyj, Marta

Zeldis, Jerome

Knight, Robert D.

Dimopoulos, Meletios

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX USA

[2] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[3] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada

[4] Univ Penn, Philadelphia, PA 19104 USA

[5] Cornell Univ, Presbyterian Hosp, New York, NY USA

[6] Celgene Corp, Summit, NJ USA

[7] Univ Athens, Sch Med, Dept Therapeut, Kifisia, Greece

来源：

BLOOD | 2006年 / 108卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3547

引用

页码：1012A / 1013A

页数：2

共 50 条

[21] MM-003, A PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE VS. HIGH-DOSE DEXAMETHASONE IN REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: OUTCOMES BY PRIOR THERAPY AND RESPONSE DEPTH
San Miguel, J. F.
Weisel, K. C.
Song, K. W.
Delforge, M.
Karlin, L.
Goldschmidt, H.
Moreau, P.
Banos, A.
Oriol, A.
Garderet, L.
Cavo, M.
Ivanova, V.
Alegre, A.
Martinez-Lopez, J.
Chen, C. I.
Renner, C.
Bahlis, N. Jacques
Yu, X.
Teasdale, T.
Sternas, L.
Jacques, C.
Zaki, M. H.
Dimopoulos, M. A.
HAEMATOLOGICA, 2014, 99 : 110 - 110
[22] Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma
Song, Kevin W.
Dimopoulos, Meletios A.
Weisel, Katja C.
Moreau, Philippe
Palumbo, Antonio
Belch, Andrew
Schey, Stephen
Sonneveld, Pieter
Sternas, Lars
Yu, Xin
Amatya, Ramesh
Monzini, Mara S.
Zaki, Mohamed
Jacques, Christian
Miguel, Jesus San
HAEMATOLOGICA, 2015, 100 (02) : E63 - E67
[23] Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma
San Miguel, Jesus F.
Weisel, Katja C.
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Moreau, Philippe
Banos, Anne
Oriol, Albert
Garderet, Laurent
Cavo, Michele
Ivanova, Valentina
Alegre, Adrian
Martinez-Lopez, Joaquin
Chen, Christine
Renner, Christoph
Bahlis, Nizar Jacques
Yu, Xin
Teasdale, Terri
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
Dimopoulos, Meletios A.
HAEMATOLOGICA, 2015, 100 (10) : 1334 - 1339
[24] MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM)
San-Miguel, Jesus F.
Weisel, Katja C.
Moreau, Philippe
Lacy, Martha
Song, Kevin W.
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Banos, Anne
Rocafiguera, Albert Oriol
Yu, Xin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed H.
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[25] IMPACT OF ECOG PERFORMANCE STATUS ON OVERALL SURVIVAL AND HRQOL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS FROM THE MM-003 TRIAL OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (DEX) vs HIGH-DOSE DEX
Weisel, K.
San Miguel, J.
Song, K.
Delforge, M.
Lewis, P.
Yu, X.
Zaki, M.
Sternas, L.
Dimopoulos, M.
HAEMATOLOGICA, 2014, 99 : 518 - 518
[26] Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
Richardson, Paul
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Malinge, Laure
Dubin, Franck
Morisse, Mony
Anderson, Kenneth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S32 - S32
[27] An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Dimopoulos, Meletios A.
Palumbo, Antonio
Corradini, Paolo
Cavo, Michele
Delforge, Michel
Weisel, Katja C.
Ocio, Enrique M.
Di Raimondo, Francesco
Hansson, Markus
Simcock, Mathew
Miller, Neil
Slaughter, Ana
Peluso, Teresa
Sternas, Lars
Zaki, Mohamed H.
Moreau, Philippe
BLOOD, 2015, 126 (23)
[28] Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide plus Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma
Palumbo, Antonio
Dimopoulos, Meletios A.
Weisel, Katja
Cavo, Michele
Ocio, Enrique M.
Corradini, Paolo
Delforge, Michel
Oriol, Albert
Goldschmidt, Hartmut
Jesus Blanchard, Maria
Conticello, Concetta
Vacca, Angelo
Hansson, Markus
Slaughter, Ana
Simcock, Mathew
Herring, Jennifer
Peluso, Teresa
Sternas, Lars
Zaki, Mohamed H.
Moreau, Philippe
BLOOD, 2014, 124 (21)
[29] ADVERSE EVENTS AND MANAGEMENT IN MM-003, A PHASE 3 STUDY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE (POM plus LODEX) VS. HIGH-DOSE DEXAMETHASONE (HIDEX) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Delforge, M.
Dimopoulos, M.
Weisel, K.
Moreau, P.
Lacy, M.
Song, K.
Karlin, L.
Goldschmidt, H.
Banos, A.
Oriol, A.
Alegre, A.
Chen, C.
Cavo, M.
Garderet, L.
Ivanova, V.
Martinez-Lopez, J.
Yu, X.
Sternas, L.
Jacques, C.
Zaki, M.
Miguel, J.
HAEMATOLOGICA, 2013, 98 : 329 - 330
[30] Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials
Quach, Hang
Harrison, Simon
Fernyhough, Liam J.
Henderson, Ross Alistair
Corbett, Gillian
Browett, Peter
Blacklock, Hilary Anne
Underhill, Craig
Cannell, Paul
Trotman, Judith
Link, Emma
Cowan, Linda
Li, Jack S.
Dimopoulos, Meletios A.
Prince, H. Miles
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →